Angela Lamarca shared post by Derek O’Reilly, Consultant surgeon at the Manchester Royal Infirmary, on X, adding:
“Adjuvant Gemcitabine and capecitabine in resected PDAC
An option to bare in mind if not fit for mFOLFIRINOX
Long-term results from ESPAC-4 now published.
Interesting analysis according to eligibility to PRODIGE-24.”
Quoting Derek O’Reilly‘s post:
“Long-term results of ESPAC-4: GemCap is a standard option for patients not eligible for mFOLFIRINOX.
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Authors: Daniel H. Palmer, Richard Jackson, Christoph Springfeld, Paula Ghaneh, Charlotte Rawcliffe, Christopher M. Halloran, Olusola Faluyi, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Pehr Lind, Bengt Glimelius, Stephen Falk, Yuk Ting Ma, Gary William Middleton, Sebastian Cummins, Paul J. Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Pascal Hammel, David Borg, Sharmila Sothi, Juan W. Valle, Arianeb Mehrabi, Peter Bailey, Christine Tjaden, Christoph Michalski, Thilo Hackert, Markus W. Büchler, John P. Neoptolemos.”
Angela Lamarca, MD, PhD, MSc, is a Consultant in Medical Oncology at Jiménez Díaz Foundation University Hospital and The Christie NHS Foundation Trust. She also serves as an Honorary Consultant in Medical Oncology and Honorary Senior Lecturer at The University of Manchester. Dr. Lamarca specializes in gastrointestinal malignancies, particularly hepato-pancreato-biliary (HPB) cancers and neuroendocrine tumors (NETs).
